Anti-CEA-CAR-T Cells is under clinical development by Shanghai First Song Therapeutics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Anti-CEA-CAR-T Cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Anti-CEA-CAR-T Cells overview
The therapeutic candidate is under development for the treatment of advanced and metastatic solid tumors including gastric cancer, colorectal cancer, esophageal cancer, small bowel cancer, pancreas adenocarcinoma and other digestive system tumors. It is administered through intravenous route and comprises of T-cells genetically engineered to express chimeric antigen receptors (CAR) targeting carcinoembryonic antigen (CEA) expressing cells.
Shanghai First Song Therapeutics overview
Shanghai First Song Therapeutics is a innovative biotechnology company provide manufacturing, developing and commercializing cell immunotherapy products. The company is headquartered in China.
For a complete picture of Anti-CEA-CAR-T Cells’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.